The FDA makes furthering moves in SCLC, ovarian, and breast cancers, and the value of remote clinical pharmacists is explored in community oncology.
HER2, a HER2-targeted immunotherapy, with plans for FDA submission following promising Phase 2b data in osteosarcoma.
HER2-positive (HER2+) breast cancer treatments come with a range of unpleasant side effects. However, there are strategies ...
OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has entered into ...
During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...
Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.
Neoadjuvant disitamab vedotin plus perioperative toripalimab has demonstrated efficacy in patients with HER2-expressing MIBC.
Eating well can help support your immune system and maintain strength and energy if you have HER2-negative breast cancer, ...
Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, discusses findings from the TROPION-Breast01 study on ...
Patients with stage IA HER2+ breast cancer and smaller tumors had high BCSS rates whether they received adjuvant chemotherapy or not.
OS Therapies (OSTX) announced that it has entered into agreements for the commercial manufacture of OST-HER2. The company is currently ...
Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparatopic antibody-drug ...